Product Search

#18411 Anti-Human VEGF (V-N) Rabbit IgG Affinity Purify

  • WB
  • Human pancreas
Intended Use:
Research reagents
Application:
WB, IHC
Package Size1:
100 μg
Package Size2:
10 μg
Note on Application Abbreviations
WB:Western Blotting
IHC:Immunohistochemistry

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
  for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
  enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 18411
Product Name Anti-Human VEGF (V-N) Rabbit IgG Affinity Purify
Intended Use Research reagents
Application WB, IHC
Species Human
Immunizing antigen Synthetic peptide of the N terminal part of Human VEGF
Purification Method Purified with antigen peptide
Specificity Reacts with both of reduced form and non-reduced form.
Package Form Lyophilized product from 1 % BSA in PBS containing 0.05% NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 100 μg
Package Size 2 10 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

Vascular Endothelial Cell Growth Factor (VEGF) is a homodimeric protein initially purified from media conditioned by normal bovine pituitary folliculo-stellate cells and secreted by a variety of vascularized tissues. It was subsequently found to be identical to a vascular permeability factor (VPF), which was previously identified in media conditioned by tumor cell lines based upon its ability to increase the permeability of capillary blood vessels. The reported activities of VEGF include stimulation of endothelial cell growth, angiogenesis and capillary permeability. Human VEGF is a 38.2kDa homodimeric protein consisting of two 165 amino acid polypeptide chains. VEGF is expressed in many human tumor cells, including human adenocarcinoma, human pancreatic carcinoma, human hepatocellular carcinoma, renal cell carcinoma, fibrosarcoma, HL60 promyelocytic leukemia, GS-9L glioma and U937 lymphoma cells. In normal tissues, VEGF expression has been observed in activated macrophages, keratinocytes, hepatocytes, smooth muscle cells Leydig cells, embryonic fibroblasts and bronchial and choroids plexus epithelium, renal glomerular visceral epithelium and mesangial cells.